Are You a Candidate for This Antibody in Patients With Mallefibrosis?

About a third of the patients have mallefibrosis calaticalin mutation and about third of the et patients uh so the number is smaller perhaps you would like everybody to be candidate but it should not be active for any other type of patients with et or mf because simply it's specific for dead mutation. After two years of therapy slowly you get CR complete molecular response not disease anymore wonderful story I hope to see it in my lifetime I hope to hear more about it in the next year well do you think we're going to see humans receive this drug in the next month? We need to go through the full drug development part and make sure it's safe in more advanced patients, says